Product Description: Denosumab (anti-TNFSF11) is a RANKL inhibitor that is effective against giant cell tumor of bone (GCTB).Denosumab eliminates RANK-positive tumor giant cells and reduces the relative content of proliferative, dense-cell tumor stromal cells[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Branstetter DG, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012 Aug 15;18(16):4415-24.